How we help you

Meaningful real-world data for Value and Access, HEOR

Volv Global provides data-driven understanding of disease endpoints and outcomes to support pricing and reimbursement calculations, regulatory and HTA submissions, payer evidence packages and comparative economics studies with real-world evidence.

Better understanding
of disease

Analyse real-world treatment pathways and their effectiveness to define more precise endpoints for better analysis of disease progression and outcomes.

Generate evidence
from credible RWD

Compare treatment effectiveness via analysis of real-world outcomes of different intervention.

Refine
value proposition

Identify cohorts more precisely and at an early stage for better longitudinal assessment of patient health outcomes.

Quantify
disease burden

Understand the real-world impact on quality of life and healthcare utilisation for payer evidence packages and comparative economic studies

Value, access and HEOR in the face of complexity

The challenge of understanding disease phenomenology

Quantifying Disease Burden

Integrating real-world evidence (RWE) to understand the real-world clinical, economic, and social impact of disease on quality of life and healthcare utilisation.

Variability in Outcomes

Disparate healthcare systems and patient populations create inconsistent datasets lacking standardised outcome measures.

Economic Attribution

Linking medical records to cost-related data is often difficult.

Population Bias

Differences in healthcare access across regions affect generalisability of findings.

Supporting Clinical Development

Actionable, state-of-the-art solutions for drug development

We find
more
patients

We find undiagnosed and misdiagnosed patients, expanding the pool of patients for clinical trial recruitment.

We detect
diseases at an
earlier stage

We find patients before the development of traditional symptoms, before they are given conventional therapies.

We predict
patient
outcomes

We enable triage of patients according to prognosis of outcomes, e.g., fast progressors, or progressors to more acute symptoms.

We stratify
patient
cohorts

We differentiate and cluster heterogeneous patient cohorts for more accurate definition of trial inclusion and exclusion criteria.

Leading AI/ML methodology to support Value and Access, HEOR

Volv Global’s inTrigue technology

Through comprehensive data integration from clinical and claims sources, inTrigue equips Value & Access and HEOR teams to quantify the real-world performance of therapies. By merging clinical, claims, and other healthcare data, inTrigue provides a holistic view of disease burden, allowing for robust cost-effectiveness and outcomes analyses. This data-backed insight aids stakeholders in demonstrating value to payers, supporting earlier detection strategies, and ultimately enhancing patient access through clearer evidence of a therapy’s impact.

Shaping the future today

Our case studies & challenges in Value and Access, and HEOR

MASH/NASH: Why Therapeutic Breakthroughs Demand a New Era of Patient Identification

- 05/12/2025

Bridging gaps across the CLL care pathway – Part 2: Knowing When To Treat

- 20/11/2025

Bridging gaps across the CLL care pathway – Part 1: From Signal to Stratification

- 04/11/2025

Cracking the Multiple Myeloma Code: Why Systemic Change is Needed to Match Therapeutic Breakthroughs

- 21/10/2025

Webinar: How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: a case study

- 05/09/2025

ATS 2024: Poster on Alpha-1 Antitrypsin Deficiency – Why millions remain undiagnosed

- 13/05/2024

Finding Patients for Rare Diseases: A Case Study

- 01/01/2024

Case Study: Detecting signs of Fabry and Pompe disease in UK clinical data

- 01/01/2023

Meaningful real-world data for Value and Access, HEOR

Better understanding of disease

Generate evidence from credible RWD

Refine value proposition

Quantify disease burden